✦ LIBER ✦

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab

✍ Scribed by Tilman Pickartz; Frauke Ringel; Marianne Wedde; Harald Renz; Andreas Klein; Nils von Neuhoff; Peter Dreger; Karl Anton Kreuzer; Christian A Schmidt; Stefanie Srock; Dagmar Schoeler; Folke Schriever

Book ID: 114216743
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 199 KB
Volume: 29
Category: Article
ISSN: 0301-472X
DOI: 10.1016/s0301-472x(01)00753-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Successful treatment and re-treatment of

Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab

✍ M. Herold; A. Schulze; K. Härtwig; G. Anger 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 46 KB

Rituximab therapy of patients with B-cel

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

✍ Huhn, D. 📂 Article 📅 2001 🏛 American Society of Hematology 🌐 English ⚖ 238 KB

Successful treatment of B-cell prolympho

Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody

✍ YasserAbou Mourad; Ali Taher; Aref Chehal; Ali Shamseddine 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 118 KB

Treatment of B-cell non-Hodgkin's lympho

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

✍ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have

Rapid tumor lysis in a patient with B-ce

Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)

✍ M. Jensen; U. Winkler; O. Manzke; V. Diehl; A. Engert 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 161 KB

CD20-negative relapse of cutaneous B-cel

CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy

✍ William Trent Massengale; Elizabeth McBurney; Jayne Gurtler 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 125 KB